Conditions: Human Immunodeficiency Virus
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 209
Healthy volunteers: no

Brief summary:
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.

Detailed description:

Arms:
arm 1: raltegravir

Interventions: intervention 1: Comparator: raltegravir
Intervention descriptions: intervention 1: 400 mg tablets taken twice daily. Total treatment period is 48 weeks.

Protocol document: